CN1036764A - 吲哚衍生物及其制备方法和含有这些化合物的药物组合物 - Google Patents
吲哚衍生物及其制备方法和含有这些化合物的药物组合物 Download PDFInfo
- Publication number
- CN1036764A CN1036764A CN89102030A CN89102030A CN1036764A CN 1036764 A CN1036764 A CN 1036764A CN 89102030 A CN89102030 A CN 89102030A CN 89102030 A CN89102030 A CN 89102030A CN 1036764 A CN1036764 A CN 1036764A
- Authority
- CN
- China
- Prior art keywords
- compound
- general formula
- hydrogen
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 103
- 150000002475 indoles Chemical class 0.000 title claims abstract description 7
- 229940054051 antipsychotic indole derivative Drugs 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 20
- -1 methylene-dioxy Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000005984 hydrogenation reaction Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000005586 carbonic acid group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 208000006218 bradycardia Diseases 0.000 description 3
- 230000036471 bradycardia Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- QXJMCSBBTMVSJS-UHFFFAOYSA-N 1-(1h-indol-2-yl)ethanone Chemical compound C1=CC=C2NC(C(=O)C)=CC2=C1 QXJMCSBBTMVSJS-UHFFFAOYSA-N 0.000 description 2
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PNFKBSVUZDKDEX-UHFFFAOYSA-N 1-[3-[(dimethylamino)methyl]-1h-indol-2-yl]ethanone Chemical class C1=CC=C2C(CN(C)C)=C(C(C)=O)NC2=C1 PNFKBSVUZDKDEX-UHFFFAOYSA-N 0.000 description 1
- RFXALDAANPMFLS-UHFFFAOYSA-N 16-epi-methuenine Natural products CC=C/1CN(C)CC2CCc3c([nH]c4ccccc34)C(=O)C12 RFXALDAANPMFLS-UHFFFAOYSA-N 0.000 description 1
- FQTFHMSZCSUVEU-UHFFFAOYSA-N 4-(2-amino-1-hydroxyethyl)benzene-1,2-diol;hydron;chloride Chemical compound Cl.NCC(O)C1=CC=C(O)C(O)=C1 FQTFHMSZCSUVEU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- METLQVFFFUYXNT-QTPGKHNVSA-N Ervatamine Chemical compound O=C1C[C@H]2[C@H](CC)CN(C)C[C@@]2(C(=O)OC)CC2=C1NC1=CC=CC=C21 METLQVFFFUYXNT-QTPGKHNVSA-N 0.000 description 1
- METLQVFFFUYXNT-UHFFFAOYSA-N Ervatamine Natural products O=C1CC2C(CC)CN(C)CC2(C(=O)OC)CC2=C1NC1=CC=CC=C21 METLQVFFFUYXNT-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GCVROCDNUNQXAD-DFZYWPJISA-N Methuenine Chemical compound O=C1C[C@H]2C(=C/C)\CN(C)C[C@H]2CC2=C1NC1=CC=CC=C21 GCVROCDNUNQXAD-DFZYWPJISA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002181 anti-sympathetic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 229910001038 basic metal oxide Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- GCVROCDNUNQXAD-HIFRSBDPSA-N methuenine Natural products CC=C1CN(C)C[C@H]2Cc3c([nH]c4ccccc34)C(=O)C[C@@H]12 GCVROCDNUNQXAD-HIFRSBDPSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明涉及吲哚衍生物,及制备该化合物的方法
含有这些化合物的药物组合物。
Description
本发明涉及吲哚衍生物,及制备该化合物的方法和含有这些化合物的药物组合物。
目前适用的降血压剂首先包括利尿剂,血管扩张剂,抗交感神经药剂,钙对抗剂,以及转化酶抑制剂,按照潜在的疾病的严重程度和菌谱,这些药剂通过不同的机理在起着作用,在某些病例中可能会产生不相容性,也可能会导致出现不希望的副作用。其结果是不仅有必要使医生停止其治疗过程,而且由于意识到能引起的某些副作用,患者也要停止接受这种治疗。
因此,对副作用发生率低的高血压需要一种有效治疗方法,这些副作用是病理性血压增高,心率加速和局部缺血性心脏病。
吲哚生物碱厄磺胺(ervatamine)(J.S.Glasby,Encyclopedia of the Alkaloids,Vol.1.(1975)和methuenine(P.Bakana,R.Dommisse,E.Esmans,R.Fokkens,J.Totte N.M.N.Nibber-ing和A.J.Vlietinck,Planta Medica,51,331/1984),这两种物质的化学结构与现有技术已知的酰基吲哚类似,但是,并不知道它们可以作为降血压剂或心搏徐缓诱发剂。
令人惊奇地发现。新合成的通式(I)吲哚化合物通过优势—受体—途径,在具备降血压作用的同时,也可使心搏徐缓。
因此,本发明提供具有通式(I)的吲哚衍生物。
其中,R1到R4可以是相同的或不同的氢或卤素原子,C1-C4-烷基,带有1-3个卤素原子的卤甲基,C1-C4-烷氧基,羟基,氨基C1-C4烷基氨基,C1-C4二烃基氨基,C1-C3烷基氨磺酰,芳基氨磺酰,C1-C3-酰氨基,C1-C3酰基,C1-C3-酰氧基,氰基,羧基,羰-C1-C4-烷氧基,亚甲二氧基或亚乙二氧基;R5和R6同是一个桥氧基,或R5或R6之一代表一个氢原子,另一个为羟基或C1-C4-烷氧基;R7和R8可以是相同或不同的氢C1-C4-烷基,苄基或C1-C3酰基团,在4和4a及5,或4a和12a位的碳原子之间的虚线可以是单或双键;或一种药理上允许的由上述化合物形成的盐类。
优选的上述烷基(包括取代烷基如烷氧基,烷氨基等)为甲基。优选的酰基为乙酰基。优选的芳基为苯基,其取代基包括1个或多个C1-C4-烷基,C1-C4-烷氧基,硝基,氨基或羟基,或卤素原子。
所谓“卤素原子”包括氟,氯,溴和碘原子,特别是氟,氯和溴原子。
当4和4a及5或4a和12a位的碳原子之间的虚线不代表双键时,即,在这些位置之间为单键时,在4a和12a位的氢原子相互之间最好为顺位。
根据本发明所优选的化合物是:通式(I)的化合物,其中R1-R4为相同或不同的1个氢原子或卤素原子,一个C1-C4-烷基,C1-C4-烷氧基,羟基或亚甲二氧基,或者药理上允许的由上述化合物形成的盐类。
根据本发明的进一步优选的化合物是通式(I)的化合物,其中R1-R4可以是相同或不同的一个氢原子或卤素原子,或一个C1-C4-烷基。优选的R7是一个氢原子,R8是一个氢原子或一个C1-C4-烷基。
更为优选的化合物,R7是一个氢原子,R5和R6同是一个桥氧基,而R8是一个甲基。
本发明也包括药理上允许的上述通式(I)的化合物形成的盐类。这些盐类可以是无机酸的酸加成盐,例如盐酸,硫酸,磷酸,或者有机酸的酸加成盐,如马来酸,富马酸,乳酸,酒石酸,苹果酸,柠檬酸等等。优选的酸加成盐为盐酸盐和半酒石酸盐及酒石酸盐。
当根据本发明的化合物含有酸基团时,也可制备与碱所成的相应盐类。这些碱包括碱金属和碱土金属氢氧化物,氨或有机胺,如单一,双一和三烷基胺,相应的羟基烷基胺等等。
本发明的化合物可以由相应的2-乙酰吲哚化合物制备。该制备方法包括下列步骤(在下列通式(I)至(V)中,符号R1到R5与上述含义相同。
步骤A
通式(II)的一种化合物与N,N-二甲基亚甲铵卤化物反应,后者按已知方法新制备的。所获得的化合物为通式(II):反应在无水溶剂中,如乙腈,二恶烷,四氢呋喃等等,反应温度为室温或高温,例如20-80℃,在惰性气体复盖下进行。步骤B
所获得的通式(II)的化合物与通式(IV)的化合物反应:
得到通式(V)的化合物:反应在适当的溶剂中进行,如乙腈或一种醚,如二恶烷,四氢呋喃,乙二醇二甲醚,或一种卤代烃,例如二氯甲烷或氯仿,等等,升高温度,最好在溶剂回流下进行。步骤C
所获得的通式(V)的化合物在碱存在条件下,反应生成通式(I)化合物。合适的碱包括:如叔丁醇钾,叔丁醇钠,叔戊醇钠等等。作为优选的溶剂为一种醚,如四氢呋喃,二恶烷乙二醇二甲醚等等。优选的反应温度为室温。
在通式(I)化合物里,R5和R6同是一个桥氧基,在4和4a,或4a和5或4a和12a位的碳原子之间的虚线有一个的键。双键的位置可由选择适当的溶剂来控制。
如果希望通式(I)化合物在虚线位置不是双键时,在惯用的氢化催化剂存在下,对不饱和产物进行氢化。不管现在的三个可能位置如何,双键都被氢化,适宜的氢化催化剂是Pd/炭,Rh/炭,Pt/炭或PtO2。氢化过程可在大气压下或升压下,在低温或高温下在适宜的溶剂中进行,溶剂的例子如醇类,如甲醇或乙醇,或一种醚如四氢呋喃。
如果希望在通式(I)的化合物中,R5和R6中的一个表示羟基或烷氧基时,则上述通式(I)化合物的R5和R6代表一个桥氧基,可还原成相应的羟基化合物,如果需要,再进行烷基化。这些反应按通常方法进行,例如,在上述的贵金属催化剂下,通过相应长的氢化过程,或借助复合金属氢化物,如氢化铝锂或硼钠氢化物通过还原,然后在强碱存在下,用例如甲醇进行烷基取代。
本发明的化合物可用于治疗人类和动物的心脏循环疾病,尤其对治疗低血压,心搏徐缓和局部性缺血性心脏病有效。
因此,本发明还提供至少含本发明的一种化合物的药剂,可任意地与药理上可接受的载体和/或辅助剂公同使用。
药剂可以按任意适当的给药方式进行配制,结合本发明的化合物,这些药剂可配制成注射剂,作成在安瓿中含一个有效的单位剂量,或在容器中含有多剂量,如必要,可加用一种适当的防腐剂。药剂也可以悬浮液,溶液,油性乳剂,和水性载体等形式存在,并含有辅助剂如悬浮剂,稳定剂和/或分散剂。
本发明的化合物也可以口服给药,如片剂,胶囊,糖衣药丸之类。作为固体状的制剂,可加入适当的辅助剂如淀粉,润滑剂的例如硬脂酸镁,阿拉伯树胶,滑石之类。
本发明的化合物也可制成栓剂,这些栓剂包含,例如传统的栓剂基剂,如可可油或其它甘油酯。
根据给药的方法,组合物中可含0.1%到多至例如0.1到99%的活性物质,如果组合物包含一单位的剂量,最好每单位含0.5至100mg活性物料。
医治患者所采用的剂量取决于各人的状况,以每天0.5到250mg的用量范围为最佳,这取决于各人状况和病的严重程度,可采用口服或肠胃外给药。
本发明的药剂也可同其它治疗剂结合使用,例如其它心脏循环剂或利尿剂。
下述实施例的目的是用于说明本发明。实施例1
(Ia)SI-WG 350步骤A:2-乙酰基-3-(N,N-二甲氨基甲基)-吲哚(SI-WG343)
187克(2摩尔)N,N-二甲基亚甲基铵氯化物在一种惰性气体存在的情况下(氮气或氩气)悬浮在28l无水乙腈中。在搅拌下,悬浮物与159克(1摩尔)粉状干燥2-乙酰吲哚混合加热至沸腾,然后继续搅拌,在7小时过程中均匀冷却至25℃。在20-25℃搅拌过夜,乙腈在真空下大体上被蒸馏出,取出的余渣放在20l水中,用浓的氢氧化溶液调节到pH9-10范围。这种溶液与二氯甲烷搅拌三次,每次加入5l的二氯甲烷。将有机相合并,并用5l水清洗。添加无水硫酸钠。将有机相干燥,过滤,再同5l叔丁基甲基醚混合。二氯甲烷被大体上蒸馏出,产物便开始结晶。在4℃下放置过夜使结晶完全,产品被抽吸过滤。用正己烷清洗,再在真空中干燥,产量141.7g(理论值的65.6%)
用同样的方法,采用适当被取代的通式(II)的2-乙酰吲哚,可获得下列通式(IIIa)的化合物;
通式(IIIa)的化合物归总在表1中。步骤B:2-乙酰-3-(N-甲基-4′-哌啶酮-3 ′-基甲基)-吲哚(SI-WG331)
140.4g(0.65摩尔)根据步骤A所获得的化合物溶解于4.8l干燥乙腈中,将293.8(2.6摩尔)N-甲基-4-哌啶酮搅拌加入,然后在回流情况下沸腾24小时。反应混合物在真空中蒸发直到残留物仍保持均匀的液态。通过在二氯甲烷中搅拌沉淀出产品,抽吸过滤,再用正己烷清洗。将母液蒸发干,与正好足量的二氯甲烷煮沸使成溶液,经过冷却,沉淀出的产品抽吸过滤,以正己烷清洗。沉淀出的产品部分与叔丁基甲基醚完全搅拌直至甲基-4-哌啶酮不再能在产品的IH-NMR光谱中见到。通过完全干燥,产品变得如此纯净,以至可在步骤C中用于环合作用。产量117.3克(理论值的63.5%)。
以同样的方法,采用适当的通式(III)和(IV)的取代前体,可获得下列通式(Va)的化合物:
通式(Va)化合物的总结见表2。步骤C:分子式为1,3,4,5,7,12-六氢-2-甲基-2H-吡啶并〔3′,4′:4,5〕-环庚并〔I,2-b〕-吲哚-6-酮的化合物制备方法:(SI-WG 334a)
113.6克(0.4摩尔)按照步骤C所获得的化合物,在惰性气体复盖下(氮或氩),温度约高达40℃下溶解在5.3l无水四氢呋喃中,然后冷却到25℃,并将134.6g(1.2摩尔)叔丁醇钾搅拌加入。反应混合物在20-25℃下搅拌30分钟。然后加入12l饱和氯化钠溶液,将生成混合物萃取三次,每次在Ultra-Turrax上加6.6l二氯甲烷。如有可能,合并的二氯甲烷相用少量饱和的氯化钠溶液清洗成中性,用无水硫酸钠干燥,过滤,再放入真空旋转蒸发器中蒸发干燥。粗制产品可直接用于氢化(步骤D)。粗制产品中的相对少量的双键异构体不会对氢化结果有不良影响。产量72.4克(理论值的68%)。
用相同方法,使用由步骤B得到的通式(V)的适当的取代化合物,可获得下列通式(Ia)不饱和化合物:
制备的化合物和该物质的数据的总结见表3。步骤D:1,3,4,4a,5,7,12,12a-八氢-2-甲基-吡啶并〔3 ′,4′:4,5〕环庚并〔1,2-b〕吲哚-6-酮标题化合物(SI-WG350)的制备:
在带有氩气放气搅拌器的氢化容器中,将72克钯活性炭(5%Pd,干态)和72克(0.27摩尔)由步骤C得到的物质加到3.5l纯四氢呋喃溶液中,氢化反应在常压,20-25℃下进行,直到氢吸收结束(60-70小时)。滤去催化剂,再将溶液在旋转蒸发器中,在真空中蒸发干燥,从甲醇里经反复结晶后获得纯的标题化合物,产量68克(理论值的94%)。
用相同方法,使用步骤C得到的经适当取代的不饱和化合物,可获得下列通式(Ia)的化合物。
制备的化合物和其物质数据总结于表4中。实施例2
按照步骤D获得的化合物(SI-WG350)转换成氢氯化物的方法。
将14.5克游离相溶解于90ml的甲醇中,在加入5.22ml 32%的含水盐酸以后,通过逐渐加入二乙基醚可使产物按定量的产率,结晶沉淀出来。
抽吸过滤掉氢氯化物后,用二乙基醚清洗,在40℃的真空下干燥,这种纯化合物的熔点为299-300℃。实施例3
化合物1,3,4,4a,5,6,7,12,12a-九氢-6-甲氧基-2-甲基-2H-吡啶并〔3′,4′:4,5〕环庚并〔I,2-b〕吲哚的制备:
(SI-WG 357)
按照步骤D获得的268mg〔1mMole〕的SI-WG350化合物溶于200ml甲醇,然后与80mg(约2mMole)硼氢化钠在室温下,以电磁搅拌器搅拌两小时。将放在旋转蒸发器的一批投料量蒸发成约20ml,与200ml水混合,并用氯仿彻底提抽。将合并的氯仿相用无水硫酸钠干燥,过滤,在真空中浓缩干燥。在硅胶60柱上,用氯仿/甲醇/水(59∶33∶8体积/体积/体积)对产品进行色谱提纯,产率:180mg非晶体物质(甲氧基差向异构体混合物,比率为4∶1)。
MS(m/e rel.int.in%):284(M+52%),269(100%),252(32%),130(25%),109(25%),96(68%),IR(KBr,cm-1):2920、2843、2782、1452、1337、1988、738,IH-NMR(CDCl3),δppm TMS=0,a*提供的相当低含量的差向异构体的识别信号):1.47-3.17(m,12H),2.25和2.31*(S,3H),3.23*和3.42(S,3H),4.34*和4.51(dd,1H),7.00-7.57(m,4H),8.21和8.42*(br.S.,1H)13c-NMR(CDCl3),δppm TMS=0,主要部分的差向异构体信号为:25.26(t),29.50(t)、33.36(d)、35.24(t)、38.17(d)、46.78(q)、55.47(t)、56.92(q)、62.03(t)、75.23(d)、110.72(d)、112.82(s)、118.45(d)、119.19(d)、121.56(d)、128.69(s)、134.53(s)、135.62(s)。实施例4:
下列化合物的制备:
1,3,4,5,7,12-六氢-2-甲基-2H-吡啶并〔3 ′,4′:4,5〕-环庚并〔I,2-b〕吲哚-6-酮(SI-WG 334a)
如果在实施例1的步骤C中,作为溶剂的不是四氢呋喃,而是相同量的1,4-二恶烷/N,N-二甲基甲酰胺,其比率为2∶1,在其它条件相同的条件下,除了SI-WG334a和SI-WG359异构体之外,会生成数量上明显优势的SI-WG360化合物。所有这三种异构体都可用硅胶60色谱法分离,在二氯甲烷/甲醇的梯度洗脱为93∶7至70∶30的情况下,可顺序地获得SI-WG359、SI-WG360和SI-WG334a。
这些化合物的物料数据,以及按相似方法制备SI-WG398(R2=Br)化合物,归总在表3中。
表1 通式(IIIa)的化合物
化合物取代基 | 经验结构式分子量 | 熔点℃ | IRKBr,(cm-1) | 1H-NMRCDCl3,δ(ppm ref to TMS=0) |
SI-WG 343R2=H | C13H16N2O216.282 | 171 | 3430,3290,3005,1645,1530,1263,749 | 2.37(s,6H),2.75(s,3H),3.93(s,2H),7.05-7.26(m,1H),7.26-7.49(m,2H),7.79(d,1H),9.52(br.s,1H). |
S1-WG 376R2=CH3 | C14H18N2O230.309 | 154 | 3320,2940,2812,2760,1634,1526,1248,799 | 2.28(s,6H),2.45(s,3H),2.80(s,3H),3.77(s,2H),7.15(dd,1H),7.41(br.d,1H),7.55(br.s,1H),9.13(br.s,1H). |
SI-WG 451R2=HC(CH3)2 | C16H22N2O258.363 | 175 | 3312,2943,2810,2758,1630,1522,1247,810 | 1.31(d,6H),2.28(s,6H),2.81(s,3H),3.02(h,1H),3.79(s,2H),7.16-7.41(m,2H)7.59(s,1H),9.08(br.s,1H). |
SI-WG 416R2=F | C13H15FN2O234.273 | 144 | 3322,2965,2933,2862,2822,2772,1640,1526,1256,1184,1168,808,722 | 2.27(s,6H),2.81(s,3H),3.75(s,2H),6.95-7.53(m,3H),9.18(br.s,1H). |
SI-WG 396R2=Br | C13H15BrNO2295.178 | 171 | 3315,2972,2938,2815,2764,1638,1527,1253,801 | 2.27(3,6H),2.81(s,3H),3.75(s,2H),7.27(dd,1H),7.40(dd,1H),7.95(br.d,1H),9.35(br,s,1H). |
SI-WG 446R2=OCH3 | C14H18N2O2246.308 | 160 | 3333,2944,2818,2783,2768,1637,1523,1219,814 | 2.28(s,6H),2.79(s,3H),3.77(s,2H),3.87(s,3H),7.02(dd,1H),7.10-7.36(m,2H)9.16(br.s,1H). |
表2 通式(Va)的化合物 表格1
化合物取代基 | 经验结构式分子量 | 熔点℃ | MSm/e(rel.Int.in%) | IRKBr(cm-1) | 1H-NMRCDCl3,δ(ppm ref toTMS=0) | |
SI-WG 331R2=HR8=CH3 | C17H20N2O2284.357 | 169 | 284(M+,5),266(0,5)173(24),158(9),130(16),112(100) | 3315,2962,2933,2842,2775,1710,1646,1530,1262,739 | 2.09-3.09(m,7H),2.28(s,3H),2.66(s,3H),3.20(br.d,1H),3.62(m,1H),7.01-7.48(m,3H),7.77(d,1H),9.01(br.s,1H), | |
SI-WG 377R2=CH3R8=CH3 | C18H22N2O2298.384 | 181 | 298(M+,5),280(0.6)187(34),172(11),144(20),112(100) | 3315,2462,2925,2843,2783,1714,1648,1534,1263,800 | 2.09-3.10(m,7H),2.29(s,3H),2.44(s,3H),2.65(s,3H),3.21(br.s,1H),3.57(m,1H),7.16(dd,1H),7.27(d,1H),7.42(br.s,1H),9.01(br.s,1H) | |
SI-WG 417R2=FR8=CH3 | C17H19FN2O2302.348 | 223 | 3315,2972,2947,2855,2794,1711,1655,1648,1538,1533,1267,1262,802 | 2.13-3.26(m,8H),2.30(s,3H),2.66(s,3H),3.57(m,1H),6.98-7.43(m,3H),8.98(br.s,1H) | ||
SI-WG 397R2=BrR8=CH3 | C17H19BrN2O2363.253 | 228 | 362/364(M+,4),344/346(2),251/253(37),236/238(24),208/210(24)125(77),112(100) | 3308,2952,2932,2852,2785,1712,1656,1532,1264,800 | 2.14-3.26(m,8H),2.31(s.3H),2.67(s,3H),3.54(m,1H),7.25(br.d,1H),7.42(dd,1H),7.84(br.s,1H),9.00(br,s,1H) |
表3 通式(Ia)的不饱和化合物(表格1)
化合物取代基 | 经验结构式分子量 | 双链的位置 | 所根据的实施例制备方法 | MSm/e(rel.Int.in%) | IRKBr(cm-1) | 1H-NMR(CDCl3)δ(ppm ref to TMS=0) | 13C-NMR(CDCl3)δ(ppm ref to TMS=0) | |
SI-WG 334aR2=HR3=CH3 | C17H18N2O266.342 | 4a-12a | 1-c | 266(M+,100),251(11),237(8),223(18).194(26),180(14),167(7),154(5),129(8),109(16),96(26) | 3298,29252893,16341529,14601336,1258740 | 2.36(s,3H),2.36(t,2H)2.48(t,2H)3.06(s,2H),3.44(s,2H),3.57(s,2H)7.15(td,1H),7.28-7.58(m,2H),7.68(d,1H),8.18(br,s,1H) | 28.26(t),31.69(t),45.24(q),48.64(t),51.93(t),59.22(t),112.14(d),120.31(d)120.48(d),124.96(s)125.22(s),126.47(b)126.98(s),132.27(s)134.01(s),135.79(s)188.22(s) | |
SI-WG 350R2=HR8=CH3 | C17H18N2O266.342 | 4a-5 | 4 | 266(M+,100)251(9),237(6),223(55),206(6),195(25),190(17),167(13),108(15),96(20) | 3282,29322780,16321577,14581327,739 | 2.05-2.56 (m,9H)2.37(s,3H),6,28(s,1H),7.03-7,49(m,3H),7.64(d,1H)9.73(br.s,1H) | 27.11(t),37.23(t),39.88(d),45.52(q),54.82(t),61.96(t),112.20(d),120.05(d)120.26(s),120.66(d)126.09(d),126.68(s)129.49(d),133.78(s)136.92(s),157.13(s)182.41(s) | |
SI-WG 360R2=HR8=CH3 | C17H18N2O266.342 | 4a-4 | 4 | 266(M+,100)251(7),238(16),223(41)206(10),195(77),180(46)167(50),108(30),94(27) | 3398,29272775,16371528,14561327,1242741 | 2.07(dd,1H),2.33(s,3H),2.54-3.40(m,6H),3.48(s,2H)5.66(br.s,1H),7.06-7.22(m,1H),7.33-7.45(m,2H),7.68(d,1H)9.20(br.S,1H) | 26.50(t),37.91(d),45.43(q),48.74(t),54.59(t),57.75(t),112.11(d),120.23(d)120.70(d),122.68(s)125.01(d),126.53(d)127.97(S),131.58(S)132.26(S),136.70(S)190.12(S), |
表3 通式(Ia)的不饱和化合物 (表格1)
化合物取代基 | 经验结构式分子量 | 双链位置 | 所根据的实施例制备方法 | MSm/e(rel.Int.in%) | IRKBr(cm-1) | 1H-NMR(CDCl3)δ(ppm ref to TMS=0) | 13C-NMR(CDCl3)δ(ppm ref to THS=0) |
SI-WG 378R2=CH3R8=CH3 | C18H20N2O280.369 | 4a-12e | 1-c | 2.19-2.63(m,4H),2.35(s,3H),2.54(5,3H)3.04(s,2H),3.42(s,2H),3.53(s,2H),7.15(d,1H),7.29(d,1H),7.44(s,1H)9.14(br.s,1H) | |||
SI-WG 418R2=FR8=CH3 | C17H17FN2O284.333 | 48-12a | 1-c | 284(M+,100),269(8),255(6),241(18),213(26),198(15),185(10)108(16),96(21) | 3297,29282897,16461530,1468802 | 2.20-2.62(m,4H),2.36(s,3H),3.05(s,2H),3.45(s,2H),3.48(s,2H),6.95-7.43(m,3H),9.20(br.s,1H) | |
SI-WG 398R2=BrR8=CH3 | C17H17BrN2O345.238 | 4a-4 | 4 | 344/346(M+,100),329/331(15),316/318(21),301/303(42),273/275(66),258/260(26),245/247(28),193(48),167(29),108(71),94(76) | 3300,29322774,16291522,14491252,797,677 | 1.96(dd,1H),2.32(s,3H),2.47-3.37(m,6H),3.48(s,2H),5.67(br.s,1H),7.27(dd,1H),7.42(dd,1H)7.81(d,1H),9.05(br.s,1H) | 26.74(t),38.06(d),45.60(q),48.34(t),54.81(t),57.94(t),113.41(s),113.64(d)121.89(s),123.33(3)125.87(d),129.38(d)129.68(s),131.03(s)133.10(s),135.10(s)190.20(s) |
表4 通式(Ia)的饱和化合物 (表格1)
化合物取代基 | 经验式分子量(高分辨) | 熔点℃ | MSm/e(rel.Int.in% | IRKBr(cm) | 1H-NMR(COCl3)δ(ppm ref to TMS=0) | 13C NMRδ(ppm ref to TMS=0) |
SI-WG 350R2=H | C17H20N2O268.358 | 184 | 268(M+,67),130(19),110(47),96(100) | 2922,2800,1660,1569,1532,1465,1447,739 | 1.70-1.95(m,2H),2.04-2.28(m,2H),2.32(s,3H)2.32-2.48(m,3H),2.54-2.64(m,2H),2.76-2.94(m,2H),3.26(dd,1H),7.12-7.19(m,1H),7.30-7.41(m,2H),7.70(d,1H)9.00(s,1H) | 26.24(t),30.94(t),31.98(d),37.57(d),45.60(t),46.39(q),53.78(t),60.61(t),112.09(d),120.26(d),120.88(d),124.81(s),126.45(d),127.32(s),133.16(s),136.43(s),193.45(s), |
SI-WG 379R2=CH3 | C18H22N2O282.384 | 210 | 282(M+,29),144(21),110(39),96(100) | 3308,2934,2763,1634,1531,1469,1447,799 | 1.63-1.96(m,2H),1.96-3.00(m,9H),2.31(s,3H),2.45(s,3H),3.24(dd,1H),7.16(dd,1H),7.29(d,1H),7.47(br.s,1H),8.79(br.s,1H) | 21.45(q),26.35(t),31.33(t),32.24(d),37.90(d),45.76(t),46.67(q),53.97(t),61.04(t),111.78(d),120.13(d),124.55(s),127.59(s),128.40(d),129.53(s),133.22(s),134.88(s),193.61(s), |
表4 通式(Ia)的饱和化合物(表格2)
化合物取代基 | 经验式分子量(高分辨) | 熔点℃ | MSm/e(rel.Int.in% | IRKBr(cm-1) | 1H-NMR(CDCl3)δ(ppm ref to TMS=0) | 13C-NMRδ(ppm ref to TMS=0) |
SI-WG 419R2=F | C17H19FN2O206.348 | 200 | 286(M+,78)148(14),110(51),96(100) | 3295,2915,2800,1662,1525,1471,794 | 1.54-1.98(m,3H),1.98-3.00(m,8H),2.32(s,3H),3.16(dd,1H),6.95-7.52(m,3H),9.15(br.s,1H) | 26.45(t),31.20(t),32.24(d),37.97(d),45.91(t),46.70(q),54.06(t),61.07(t),105.24(dd),113.15(dd),115.47(dd),125.00(d),127.50(d),133.00(s),134.50(5),157.50(d),193.71(s). |
SI-WG 399R2=Br | C17H19BrN2O347.2538 | 243 | 346/348(M+,17)208/210(3),110(44),96(100) | 3300,2930,2797,1633,1529,1460,799 | 1.63-1.98(m,2H),1.98-2.96(m,9H),2.32(s,3H),3.18(dd,1H),7.30(d,1H),7.42(dd,1H),7.85(d,1H),9.01(br.s,1H) | 26.31(t),31.16(t),32.25(d),38.00(d),45.89(t),46.68(q),54.04(t),61.06(t),113.25(s),113.59(d),123.53(d),124.15(s),128.95(s),129.27(d),133.95(s),134.00(s),193.75(s). |
SI-WC 449R2=OCH3 | C18H22N2O2298.384 | 216 | 298(M+,62),160(21),110(52),96(100) | 3288,2922,2775,1626,1523,1464,1211,803 | 1.58-1.97(m,2H),1.97-3.03(m,9H),2.32(s,3H),3.21(dd,1H),3.88(s,3H),6.96-7.16(m,2H),7.29(dd,1H),8.81(br.s,1H) | 26.49(t),31.25(t),32.32(d),37.99(d),45.85(t),46.73(q),54.11(t),55.78(q),61.18(t),100.94(d),113.07(d),118.14(d),124.44(s),127.61(s),131.81(s),133.68(s),154.50(s),193.47(s). |
盖仑制剂实例
片剂
1)SI-WG350.HCl 10.00kg
2)微晶纤维素pH102 40.00kg
3)乳糖.1H2O 12.85kg
4)玉米淀粉 16.00kg
5)玉米淀粉 0.50kg
6)硬脂酸镁 0.25kg
80.00kg
将1)、2)、3)、和4)装在捏合机(一种混合成粒装置)中混合20分钟。接着把10l5%的5)水溶液加入混合物,再混合30分钟。混合物过筛,干燥并再过筛。此后,获得的颗粒和6)在上述装置中混合30分钟,并接着将混合团块压成片剂,例如直径6mm,重量80mg的片剂。针剂
1)SI-WG350.HCl 0.100kg
2)柠檬酸-水化物 0.470kg
3)柠檬酸三钠二水化物 0.530kg
4)氯化钠 0.625kg
5)注射水 到100l在适当的容器中把成分1)、2)、3)和4)溶于5)中。溶液经无菌过滤,将每份为1ml溶液注入小瓶,再进行蒸气-消毒。
不仅对片剂,而且对针剂,都可用通式I及通式V的化合物来代替1)。
药理研究
现已发现,所说的物质可不同程度地改变循环性能计量值,此处所用的生物试验方法的描述可参见:Staff of theDepartment of Pharmacology,University of Edin-burgh,和L.J.McLeod(1970):PharmacologicalExperiment in Intact Preparations,ChurchillLivingstone Edinburgh,London and New York,Page62。
在对6-8只为一组的老鼠以半一酒石酸盐形式进行静脉注射时,可采用本发明的化合物,其用量为10mg kg-1。0.9%氯化钠溶液作为化合物的溶剂。注射0.9%氯化钠溶液作为对照液。在试验的开始前和结束时,抽取血样并测定血内气体浓度。
对麻醉后的老鼠给了本化合物药物后,在两小时内监测血压和心率的变化,决定各种情况下的最大效应,其结果见表5。
可以看出,施用本发明的化合物时,所服用量决定了老鼠的心率和血压下降的程度。
进而还可发现当采用另一种方式给药时,本发明的化合物对其它种类试验动物的作用,特别是SI-WG350-25-在对老鼠和猫的十二指肠用药的情况下,更低的有效剂量为1mg kg-1。
在对心血管有效的服用剂量范围内,权利要求的化合物不会影响其本能的行为和活动。它们也不起止痛作用,因此在对老鼠采用通常的技术进行适当研究时,可以证实这点。
既使对老鼠despinalisation之后,用SI-WG350,以及本发明的其它化合物时仍可导致血压和心率的下降。
采用自发地搏动豚鼠的左右心房其刺激频率为1Hz,这项单独的研究结果,以及上述结果都证实,该权利要求的化合物对心脏具有直接的活动机理,这项试验采用的方法的叙述可参见:Staff ofthe Department of Pharmacology,University ofEinburgh 1(1970):Pharmacological Experiments onIsolated Preparation,Churchill Livingston,Edinburgh,London and New York,Page 112。
把体重约500g的动物分成4只一组进行实验,被试验的化合物溶于台罗德氏溶液/氯化钠溶液中,其体积之比为50∶50,将浴液的浓度调节到理想值,按已知方法进行实验,其实验结果见表6。
在对麻醉的老鼠进行通常的研究时,可以证实,本权利要求的物质对组胺释放或胆固醇释放的机理没有相互作用。同样,它们也不会引起β-肾上腺受体-阻碍作用,因此可对肾上腺受体的可能的影响进行研究。
在体重约15kg的雌性小猎兔犬上可以测定对抗作用,被试验的化合物(以半一酒石酸盐形式)溶于台罗德氏液中,芬妥胺作为参照物质(参照对抗物),为了对照起见,台罗德液单独使用,参照对抗物是DL-去甲肾上腺素氢氯化物。
按已知方法制备血液容器部分和进一步进行的试验,根据J.M.Van Rossum(Arch.int.Pharmacodyn., 143(3-4),299-330/1963)和H.O.Schild(Pharmacol.Rev., 9242/1957)的方法进行定量评估和计算。作为实例的结果见下表:
化合物 PA2±S-----------------------------------------------------
SI-WG350 6.88±0.73
SI-WG357 6.88±0.27
芬妥胺 7.19±0.68
采用将受体结合/置换研究的方法,加强化合物对α-肾上腺受体-特殊点的刺激,其中,对SI-WG350化合物,将浓度为3.3×10-8M标记的配位体3H-Prazoin替换50%(IC50值)已被确定,(芬妥胺=1.8×10-8M)。没有发现在与3H-Prazion竞争中,对α2-受体有阻碍作用,用相关的配位体的类似试验方法证实试验中不存在对β-受体和钾-和钠-特殊结合点的竞争。
表5
心脏频率的 血压变化范化合物 剂量
改变(%) 围压力(%)SI-WG 350 1mg/kg i.v. -14.5 -15.8
2mg/kg i.v. -21.9 -16.5
5mg/kg i.v. -28.4 -31.5
2mg/kg i.d. -7.2 -19.2
5mg/kg i.d. -23.0 -25.7SI-WG357 5mg/kg i.v. -6.1 -11.6
10mg/kgi.v. -5.5 -22.9SI-WG334a 2mg/kg i.v. -21.2 -17.2
5mg/kg i.v. -19.6 -25.9
10mg/kgi.v. -20.8 -30.1SI-WG360 2mg/kg i.v. -10.7 -10.3
5mg/kg i.v. -14.3 -23.0
10m/kg i.v. -22.2 -34.2SI-WG331 5mg/kg i.v. -- --
20mg/kgi.v. -9.7 -18.4
50mg/kgi.v. -19.3 -29.1SI-WG379 5mg/kg i.v. -17.4 -19.2
10mg/kgi.v. -23.9 -22.0SI-WG399 2mg/kg i.v. -- --
5mg/kg i.v. -6.6 --
10mg/kgi.v. -12.1 --SI-WG419 2mg/kg i.v. -7.5 -10.6
5mg/kg i.v. -12.1 -21.4
10mg/kgi.v. -22.8 -26.7SI-WG449 2mg/kg i.v. -- -16.0
5mg/kg i.v. -12.0 -10.0
10mg/kgi.v. -17.0 -22.0
表6初始的最大影响%化合物 剂量 左心房 右心房SI-WG 350 2.0μg/ml +16 -25
10.0μg/ml +17 -31
20.0μg/ml +23 -47SI-WG 331 2.0μg/ml +8 -7
10.0μg/ml +14 -12
20.0μg/ml +31 -23SI-WG 334a 2.0μg/ml +26 -14
10.0μg/ml +25 -29
20.0μg/ml +33 -43SI-WG 357 2.0μg/ml +17 -9
10.0μg/ml +32 -19
20.0μg/ml +24 -19SI-WG 360 2.0μg/ml +17 -10
10.0μg/ml +39 -29
20.0μg/ml +50 -41SI-WG 379 0.5μg/ml +8 -14
20μg/ml +24 -35
4.0μg/ml +24 -46
10.0μg/ml +23 -81SI-WG 399 0.5μg/ml ±5 -22
2.0μg/ml +25 -43
4.0μg/ml +13 -66
10.0μg/ml ±5 -83SI-WG 419 0.5μg/ml +6 -18
2.0μg/ml +6 -30
4.0μg/ml -7 -42
10.0μg/ml -27 -80SI-WG 449 2.0μg/ml +16 -19
10.0μg/ml +23 -40
20.0μg/ml +20 -57+++=实验期满前的收缩调节
兼容性
本发明的化合物兼容性很好,在对老鼠采取口服给药时,所测量的毒性为150-225mg/kg,在用静脉注射时,对老鼠的LD50值为24.0-34.0mg/kg。
考虑到所定的LD50值以及治疗患者服量,可见具有广泛疗效。
Claims (9)
1.一类具有通式(I)的吲哚衍生物其中R1到R4(可以是相同或不同)为氢或卤素原子,C1-C4-烷基,1-3个卤原子卤甲基,C1-C4-烷氧基、羟基、氨基、C1-C4-烷基氨基、C1-C4-二烷基氨基、C1-C3-烷基磺酰氨、芳基磺酰氨、C1-C3-酰氨基、C1-C3-酰基、C1-C3-酰氧基、氰基、羧基、羰-C1-C4-烷氧基、亚甲二氧基或亚乙二氧基:R5和R6同为一个桥氧基,或R5或R6之一为氢原子,另一个基是羟基,或者C1-C4-烷氧基,R7和R8(可为相同或不同)为氢,或C1-C4-烷基,苄基或C1-C3-酰基,及4和4a,或4a和5,或4a和12a位上的碳酸原子之间的虚线可以表示一个单或双键;或者是一种药理所允许的它的盐。
2.根据权利要求1的通式(I)的一种化合物,其中R1到R4为氢或卤素原子,C1-C4-烷基、C1-C4-烷氧基、羟基、或一个亚甲二氧基,或一种药理所允许的它的盐。
3.根据权利要求1的通式(I)的一种化合物,其中R1到R4为氢或卤素原子,或C1-C4-烷基,R7为一个氢原子,及R8为一个氢原子,或一个C1-C4-烷基,或者药理所允许的它的盐。
4.一种具有结构
的化合物。
5.一种制备如权利要求1~4中任意一项所要求的通式(I)的化合物的方法,包括步骤:
A)通式(II)的化合物:与N,N-二甲基亚甲基铵卤化物反应,得到通式(II)的化合物:
C)通式(V)的化合物通过一种碱处理转化为通式(I)的化合物,其中R5和R6为一桥氧基,且虚线代表一个双键;或任选的:
D)需要的话,通式(I)的化合物在一惰性溶剂中于催化剂存在下氢化得到一个通式(I)的化合物,其中,4和5位表示亚甲基,4a和12a位的氢原子相互定向为顺式;或还原为通式(I)的化合物,其中R5或R6中的一个为羟基,或通式(I)的化合物为烷基化了的通式(I)的化合物,其中R5和R6中的一个为C1-C4-烷氧基;和任选的:
E)需要的话,通过一种酸或一种碱处理所得通式(I)的化合物以药理所允许的盐。
6.一种药剂,它含有至少一种根据权利要求1至4之一的化合物,任意地和一个药理所允许的载体或辅助剂在一起。
7.使用至少一种根据权利要求1至4之一的化合物治疗心脏—循环疾病。
8.一种具有通式(V)的中间化合物:
其中,R1~R4,R7和R8的含义由权利要求1给出。
9.一种具有结构式(VI)的中间化合物:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3807533A DE3807533A1 (de) | 1988-03-08 | 1988-03-08 | Pyridocycloheptindol-verbindungen, verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten |
DEP3807533.4 | 1988-03-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1036764A true CN1036764A (zh) | 1989-11-01 |
CN1024551C CN1024551C (zh) | 1994-05-18 |
Family
ID=6349134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN89102030A Expired - Fee Related CN1024551C (zh) | 1988-03-08 | 1989-03-07 | 吲哚衍生物的制备方法 |
Country Status (30)
Country | Link |
---|---|
US (1) | US5159080A (zh) |
JP (1) | JPH0613514B2 (zh) |
KR (1) | KR910004449B1 (zh) |
CN (1) | CN1024551C (zh) |
AT (1) | AT395243B (zh) |
AU (1) | AU610701B2 (zh) |
BE (1) | BE1002923A4 (zh) |
CH (1) | CH677792A5 (zh) |
CZ (1) | CZ143789A3 (zh) |
DD (1) | DD283622A5 (zh) |
DE (1) | DE3807533A1 (zh) |
DK (1) | DK110089A (zh) |
FI (1) | FI92066C (zh) |
FR (1) | FR2628426A1 (zh) |
GB (1) | GB2216889B (zh) |
GR (1) | GR1000311B (zh) |
HU (1) | HU205355B (zh) |
IE (1) | IE61683B1 (zh) |
IL (1) | IL89476A (zh) |
IT (1) | IT1228569B (zh) |
LU (1) | LU87463A1 (zh) |
NL (1) | NL8900552A (zh) |
NO (1) | NO890978L (zh) |
NZ (1) | NZ228246A (zh) |
PL (1) | PL159893B1 (zh) |
PT (1) | PT89941B (zh) |
SE (1) | SE500580C2 (zh) |
SU (1) | SU1650012A3 (zh) |
YU (1) | YU48489A (zh) |
ZA (1) | ZA891721B (zh) |
-
1988
- 1988-03-08 DE DE3807533A patent/DE3807533A1/de active Granted
-
1989
- 1989-03-01 LU LU87463A patent/LU87463A1/fr unknown
- 1989-03-02 SE SE8900725A patent/SE500580C2/sv unknown
- 1989-03-02 GB GB8904792A patent/GB2216889B/en not_active Expired - Fee Related
- 1989-03-02 AT AT0047389A patent/AT395243B/de not_active IP Right Cessation
- 1989-03-02 CH CH807/89A patent/CH677792A5/de not_active IP Right Cessation
- 1989-03-03 IL IL8947689A patent/IL89476A/en unknown
- 1989-03-03 IT IT8919648A patent/IT1228569B/it active
- 1989-03-03 IE IE70089A patent/IE61683B1/en not_active IP Right Cessation
- 1989-03-07 CN CN89102030A patent/CN1024551C/zh not_active Expired - Fee Related
- 1989-03-07 NZ NZ228246A patent/NZ228246A/en unknown
- 1989-03-07 GR GR890100145A patent/GR1000311B/el unknown
- 1989-03-07 DD DD89326336A patent/DD283622A5/de not_active IP Right Cessation
- 1989-03-07 KR KR1019890002754A patent/KR910004449B1/ko not_active IP Right Cessation
- 1989-03-07 NL NL8900552A patent/NL8900552A/nl not_active Application Discontinuation
- 1989-03-07 DK DK110089A patent/DK110089A/da not_active Application Discontinuation
- 1989-03-07 FR FR8902978A patent/FR2628426A1/fr active Granted
- 1989-03-07 NO NO89890978A patent/NO890978L/no unknown
- 1989-03-07 AU AU31095/89A patent/AU610701B2/en not_active Ceased
- 1989-03-07 ZA ZA891721A patent/ZA891721B/xx unknown
- 1989-03-07 SU SU894613697A patent/SU1650012A3/ru active
- 1989-03-07 HU HU891112A patent/HU205355B/hu not_active IP Right Cessation
- 1989-03-07 CZ CS891437A patent/CZ143789A3/cs unknown
- 1989-03-07 YU YU00484/89A patent/YU48489A/xx unknown
- 1989-03-08 PL PL1989278135A patent/PL159893B1/pl unknown
- 1989-03-08 JP JP1053974A patent/JPH0613514B2/ja not_active Expired - Lifetime
- 1989-03-08 PT PT89941A patent/PT89941B/pt not_active IP Right Cessation
- 1989-03-08 BE BE8900249A patent/BE1002923A4/fr not_active IP Right Cessation
- 1989-03-08 FI FI891086A patent/FI92066C/fi not_active IP Right Cessation
-
1990
- 1990-12-18 US US07/629,188 patent/US5159080A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1056607C (zh) | 三环吡唑衍生物 | |
CN101041629B (zh) | 阿戈美拉汀的新合成方法、新晶型及其药物组合物 | |
US7683052B2 (en) | Crystalline polymorph of bazedoxifene acetate | |
JP2019516795A (ja) | (S)−N−(5−((R)−2−(2,5−ジフルオロフェニル)ピロリジン−1−イル)−ピラゾロ[1,5−a]ピリミジン−3−イル)−3−ヒドロキシピロリジン−1−カルボキサミドの調製 | |
CN1845674A (zh) | 一种二肽基肽酶iv抑制剂的磷酸盐新晶体 | |
CN1832949A (zh) | 二肽基肽酶-iv抑制剂的磷酸盐 | |
JP2009035535A (ja) | バゼドキシフェンアセテートの結晶多形 | |
US20200148681A1 (en) | Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing | |
CN100345840C (zh) | 毒蕈碱性受体拮抗剂的稳定水合物 | |
CN1023399C (zh) | 制备新的8-取代的2-氨基-1,2,3,4-四氢化萘类化合物的方法 | |
CN1049349A (zh) | 新的2-氧代-3,8-二氮杂螺[4,5]癸烷衍生物,含有这些衍生物的药物配方及其制备方法 | |
CN1033451C (zh) | α-取代的苯甲胺衍生物 | |
CN1009826B (zh) | 制备喹啉基化合物的方法 | |
CN1055739A (zh) | 半水合物 | |
CN1320036A (zh) | 治疗胃-食管返流性疾病的方法和组合物 | |
CN1279018C (zh) | 一种制备右旋α-[2-(萘氧基)乙基]苯甲胺衍生物的方法 | |
CN1498216A (zh) | 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法 | |
CN1036764A (zh) | 吲哚衍生物及其制备方法和含有这些化合物的药物组合物 | |
US7595340B2 (en) | Serotonin and norepinephrine reuptake inhibitor and uses thereof | |
GB2032423A (en) | N - phenyl-indoline derivatives their production and pharmaceutical compositions containing them | |
CN1305474A (zh) | 帕罗西汀马来酸盐 | |
CN1217953C (zh) | 具有心血管活性的黄杨宁类化合物及以其为活性成分的心脑血管药物 | |
CN1148594A (zh) | 哌啶基甲基噁唑烷酮 | |
CN102459174A (zh) | 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]喹唑啉的制备方法 | |
CN1102649A (zh) | 哌啶和派嗪衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |